Journey Medical Corp (DERM) - Total Assets
Based on the latest financial reports, Journey Medical Corp (DERM) holds total assets worth $94.59 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Journey Medical Corp - Total Assets Trend (2014–2025)
This chart illustrates how Journey Medical Corp's total assets have evolved over time, based on quarterly financial data. Also see DERM stock market capitalisation for the company's overall valuation and market capitalisation.
Journey Medical Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Journey Medical Corp's total assets of $94.59 Million consist of 70.7% current assets and 29.3% non-current assets. Review Journey Medical Corp (DERM) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.5% |
| Accounts Receivable | $29.78 Million | 31.5% |
| Inventory | $9.62 Million | 10.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $27.61 Million | 29.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Journey Medical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Journey Medical Corp for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Journey Medical Corp's current assets represent 70.7% of total assets in 2025, an increase from 59.2% in 2014.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, down from 31.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 31.5% of total assets.
Journey Medical Corp Competitors by Total Assets
Key competitors of Journey Medical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Journey Medical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.37 | 1.26 |
| Quick Ratio | 1.53 | 0.96 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.43 Million | $13.00 Million | $7.18 Million |
Journey Medical Corp - Advanced Valuation Insights
This section examines the relationship between Journey Medical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.35 |
| Latest Market Cap to Assets Ratio | 1.45 |
| Asset Growth Rate (YoY) | 17.9% |
| Total Assets | $94.59 Million |
| Market Capitalization | $136.73 Million USD |
Valuation Analysis
Above Book Valuation: The market values Journey Medical Corp's assets above their book value (1.45x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Journey Medical Corp's assets grew by 17.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Journey Medical Corp (2014–2025)
The table below shows the annual total assets of Journey Medical Corp from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $94.59 Million | +17.88% |
| 2024-12-31 | $80.24 Million | +4.41% |
| 2023-12-31 | $76.85 Million | -26.92% |
| 2022-12-31 | $105.16 Million | +8.10% |
| 2021-12-31 | $97.28 Million | +87.42% |
| 2020-12-31 | $51.91 Million | +53.30% |
| 2019-12-31 | $33.86 Million | -90.17% |
| 2018-12-31 | $344.32 Million | -38.60% |
| 2017-12-31 | $560.79 Million | +79.40% |
| 2016-12-31 | $312.60 Million | +40.85% |
| 2015-12-31 | $221.93 Million | +24.53% |
| 2014-12-31 | $178.22 Million | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more